Pay in 4 interest-free payments of $6.49 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Synaptogenic effects complement neurogenic activity
It's also the section most people skip, which is a mistake
We calculate optimistic and pessimistic scenarios by flexing these key assumptions to plausible higher and lower values
There's a lot to unpack, so we've structured our thoughts into three distinct sectionsfeel free to peruse the whole post or jump forward to specific areas of interest using the links below: We'll start by sharing our about where the innovation race is headingand what it means for the industry key insights and predictions From there, we'll overview (including key differentiators between major competitors Eli Lilly and Novo Nordisk) what the race has looked to date Finally, we'll go deep on the that will define the innovation race moving forward: five vectors of innovation GLP-1 innovation: Key insights and predictions GLP-1s are more than a blockbuster drug class, they signal a profound reordering of how chronic disease is managed, financed, and even understood
